Lonza Q1 Business Performance on Track
"In the first quarter of 2014, Lonza’s business performance was fully in line with our expectations. In both the Specialty Ingredients and Pharma&Biotech segments, we realized our growth targets and achieved a better performance than in the same period of the previous year. We experienced considerable translational currency impact from the strong Swiss franc, but we were able to compensate the bottom-line impact in the first quarter by productivity improvements."
Richard Ridinger, CEO of Lonza, said: “I’m pleased with the performance of our businesses in the first quarter. The good results show that we have embarked on the right path with our transformational initiatives, which make us more competitive and more market oriented. We also continue to work diligently on operational improvements and quality initiatives across the company in all regions.”
Pharma & Biotech Segment
The Pharma & Biotech segment saw an uptake in demand across all technologies and offerings. In custom manufacturing several new contracts were concluded, and the start-up of second large-scale ADC facility in Visp (CH) is on schedule for Q2 2014. Microbial Development Services successfully executed the process transfer of four customer projects from Hopkinton, MA (USA) to Visp. Demand was strong throughout the first quarter for mammalian cell-line construction programs in Slough and Singapore. In our bioscience solutions business, we experienced a strong recovery within the European research business, whereas Lonza experienced conservative spending in the US research market. As expected, the Media business had good performance.
In summary, overall results for the first quarter, as well as our improvement projects emphasizing organic growth and quality matters, are all fully on track. Lonza’s financial situation is solid. Based on constant exchange rates, we are on track to deliver a revenue growth of ~5% and a CORE EBIT growth of ~10% in 2014.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance